Table 1.
Patient, donor and transplant characteristics.
| ATLG | PTCY | p | |
|---|---|---|---|
| N (%) | N (%) | ||
| Patient age median (range) | 29 (18–61) | 42 (18–79) | <0.001 |
| Age ≤36 | 49 (66) | 24 (33) | <0.001 |
| Age >36 | 25 (34) | 49 (67) | |
| ALL | 0.02 | ||
| B | 49 (66) | 64 (88) | |
| T | 25 (34) | 9 (12) | |
| BCR-ABL | 0.006 | ||
| – | 14 (935) | 40 (63) | |
| + | 26 (65) | 24 (38) | |
| MRD at transplant | 0.38 | ||
| – | 10 (48) | 38 (59) | |
| + | 11 (52) | 27 (42) | |
| SCT year median (range) | 2003 (1993–2015) | 2020 (2014–2023) | <0.001 |
| SCT ≤ 2014 | 72 (37) | 2 (3) | <0.001 |
| SCT > 2014 | 2 (3) | 71 (97) | |
| Type of donor | 0.006 | ||
| MRD | 9 (12) | 18 (25) | |
| MMRD | 3 (4) | 10 (14) | |
| MUD | 34 (46) | 32 (44) | |
| MMUD | 28 (38) | 13 (18) | |
| Patient / Donor Sex | 0.06 | ||
| M/M | 32 (43) | 28 (38) | |
| M/F | 13 (18) | 7 (10) | |
| F/F | 18 (24) | 14 (19) | |
| F/M | 11 (15) | 24 (33) | |
| Patient / Donor CMV | 0.5 | ||
| –/– | 22 (30) | 19 (26) | |
| –/+ | 12 (16) | 7 (10) | |
| +/+ | 27 (37) | 34 (47) | |
| +/– | 13 (18) | 13 (918) | |
| ABO incompatibility | 0.073 | ||
| Compatible | 29 (39) | 44 (60) | |
| Minor incompatibility | 19 (26) | 11 (15) | |
| Major incompatibility | 18 (24) | 11 (15) | |
| Bidirectional incompatibility | 8 (11) | 7 (10) | |
| Donor Age median (range) | 40 (15–65) | 30 (18–72) | <0.001 |
| Age ≤37 | 34 (46) | 44 (60) | 0.082 |
| Age >37 | 40 (54) | 29 (40) | |
| Stemcell source | <0.001 | ||
| BM | 28 (38) | 8 (11) | |
| PBSC | 46 (62) | 65 (89) | |
| CD34 infused cells median (range) | 6.6 (0.6–31) | 6.8 (1.5–11.4) | 0.8 |
| ≤6.7 × 106/kg BW | 38 (51) | 36 (49) | |
| >6.7 × 106/kg BW | 36 (49) | 37 (51) | |
| Conditioning | <0.001 | ||
| TBI+Cy+Vp16 | 52 (70) | 0 (0) | |
| TBI+Cy | 22 (30) | 0 (0) | |
| TBI+Flu | 0 (0) | 73 (100) | |
| TBI dose | <0.001 | ||
| 8.0 | 0 (0) | 22 (30) | |
| 10.0 | 1 (1) | 1 (1) | |
| 12.0 | 73 (99) | 50 (69) | |
| ATLG dose | |||
| 30.0 | 11 (15) | ||
| 40.0 | 1 (1) | ||
| 60.0 | 29 (39) | ||
| 90.0 | 26 (35) | ||
| other | 7 (10) | ||
| Immune suppression | <0.001 | ||
| MTX + CSA | 50 (67) | 0 (0) | |
| MMF + CSA | 22 (30) | 35 (48) | |
| MMF + TAC | 0 (0) | 24 (33) | |
| Unknown | 2 (3) | 14 (19) | |
Bold values indicate statistical significance p < 0.05.
ALL acute lymphoblastic leukemia, ATLG anti-t-lymphocyte globulin, PTCy post- transplant cyclophosphamide, SCT stem cell transplantation, MRD minimal residual disease, MRD matched related donor, MMRD mismatch related donor, MUD matched unrelated donor, MMUD mismatched unrelated donor, CMV cytomegalo virus, BM bone marrow, PBSC peripheral blood stem cell, Cy cyclophosphamide, Vp16 etoposide, Flu fludarabine, TBI total body irradiation, CSA cyclosporine A, MMF mycophenolate mofetil, MTX methotrexate, TAC tacrolimus.